http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-202092206-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate | 2019-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-202092206-A1 |
| titleOfInvention | DIHYDROCHROMENE DERIVATIVES |
| abstract | The invention relates to a compound of formula (I), where R1A, R1B, R1C and R1D represent a hydrogen atom, etc., R2A and R2B represent a hydrogen atom, etc., R3A, R3B, R3C and R3D represent an atom hydrogen, etc., L is a bond, etc., V is C1-6 alkylene, Q is an optionally substituted imidazole, or a pharmaceutically acceptable salt thereof as a novel anti-tumor agent targeting CSCs believed to be , are directly involved in the ongoing growth of malignant tumors, metastasis or recurrence of cancer and resistance to anticancer agents. |
| priorityDate | 2018-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546850 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID795 |
Total number of triples: 17.